markets

NextPlat Posts 35% Gross Profit Gain, Cuts Net Loss by 66% in Q3

Summarized from Earnings

NextPlat Corp reported stronger third-quarter results driven by 340B pharmacy growth and expanding margins across its consolidated operations.

NextPlat Posts 35% Gross Profit Gain, Cuts Net Loss by 66% in Q3

NextPlat Corp (NASDAQ: NXPL), a Hallandale Beach, Florida-based global consumer products and services company, reported third-quarter financial results showing nearly 35% improvement in year-over-year gross profit alongside a consolidated quarterly gross margin of 35%, the company announced Nov. 12.

The company also reduced its net loss by approximately 66% compared to the same period a year earlier, a signal that cost controls and higher-margin revenue streams are beginning to take hold across the business.

Read more IQSTEL Posts $313M Nine-Month Revenue on 34.5% Organic Growth →

A key driver of the improved performance was a 72% surge in prescription volumes tied to the federal 340B drug pricing program, which allows eligible healthcare organizations to purchase medications at significantly reduced costs. NextPlat has been actively expanding its pharmacy footprint, and the volume growth in that segment reflects the early returns of that strategy.

The quarter's results suggest NextPlat is making measurable progress in shifting its revenue mix toward higher-margin business lines. Sustained 340B volume growth, if maintained, could continue to lift overall margins in future quarters as the pharmacy segment matures within the company's broader portfolio.

Continue reading at Earnings.

Frequently Asked Questions

Q.How much did NextPlat reduce its net loss in Q3?

NextPlat reduced its net loss by approximately 66% compared to the same quarter a year earlier.

Q.What drove NextPlat's gross profit improvement in the third quarter?

The improvement was driven by a 72% increase in higher-margin 340B prescription volumes and an expanded pharmacy footprint, contributing to a consolidated gross margin of 35%.

Q.What is the 340B program and why does it matter for NextPlat?

The 340B program is a federal initiative that allows eligible healthcare entities to purchase drugs at reduced prices. NextPlat's strong growth in 340B prescription volumes was a primary contributor to its improved quarterly margins.

More in markets →